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Acute heart failure (HF) is a leading cause of hospitalization, particularly in elderly 
people, and has an unacceptably dismal prognosis. The occurrence of acute kidney injury in 
the setting of a HF decompensation [type 1 cardio-renal syndrome (CRS)] has been 
suggested to be one of the most powerful determinants of outcome, and its recognition is 
essential to develop strategies aimed at improving our current treatment options and the 
outcomes of this population. Glomerular filtration rate (GFR) is the most useful index of 
kidney function, and changes in serum creatinine have generally been used clinically as 
surrogates for changes in GFR. Creatinine levels are influenced by several factors, and have 
low sensitivity to detect small decreases in GFR and a long delay period in achieving steady 
state. These characteristics make it an unreliable measure for accurate and timely 
diagnosis of kidney damage, and even for kidney dysfunction. Recent research has moved 
the focus towards potentially better and more sensitive biomarkers of kidney damage and 
function. Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C are two 
promising renal biomarkers. 
NGAL is an early marker of renal tubular damage that predicts the development of 
acute kidney injury in several settings, including acute HF. NGAL also revealed to have a 
prognostic role, but this has not been addressed in the HF population. Cystatin C is mainly a 
marker of renal function, but more sensitive and earlier than serum creatinine, and several 
cystatin C-based equations estimating GFR have been proposed. In comparison to serum 
creatinine and creatinine-based GFR estimating equations, serum cystatin C and cystatin C-
based equations are similarly good markers of prognosis stratification in HF populations. 
We aimed to explore the role of NGAL and cystatin C in diagnostic and prognostic 
assessment of acute renal injury in acute HF patients, addressing their performance in the 
early detection of type 1 CRS and their role in the short-term prognostic stratification in 
these patients. We also assessed the discrimination and predictive value of cystatin C- and 
creatinine-based GFR estimating equations, as well as a combined cystatin C- and 
creatinine-based eGFR equation, in predicting medium-term prognosis in acute HF patients, 
and, additionally, determined the possible added value of cystatin C in risk stratification in 
this population, compared to creatinine-based estimated GFR alone. 
In our real world elderly acute HF population, a single NGAL measurement, at the 
first hospitalization morning, could identify all patients developing type 1 CRS within 48 to 
72 hours with a 50% false positive rate and an area under the curve 0.93. No patient with 
<170 ng/mL first-morning NGAL developed type 1 CRS, and half of the patients with a first-
morning value >170 ng/mL developed type 1 CRS. We concluded that serum NGAL 
anticipated the development of type 1 CRS, and therefore can help clinicians in the early 
recognition of patients developing very short-term renal deterioration. Serum NGAL levels 
at hospital admission were independently associated with short-term adverse outcomes, 
with levels above 167.5 ng/mL predicting a 2.7-fold increase in the risk of death from all 
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causes and a 2.9-fold increase in the risk of the first occurrence of either death or 
hospitalization. These results suggest a prognostic role of renal damage, besides that of 
renal function, upon the beginning of acute HF episodes. Additionally, we observed that 
renal function, measured at hospital discharge, is a major factor affecting medium-term 
adverse outcomes in acute HF, with the risk of 6-month death increasing progressively 
across categories of estimated GFR for all estimating equations used. In patients with 
normal renal function or with severe renal dysfunction, creatinine-based methods for 
estimating GFR, particularly the Cockcroft-Gault equation, were accurate predictors of 
prognosis. However, in patients with estimated GFR 30-59 mL/min/1.73 m2 according to the 
Cockcroft-Gault equation, who had a 6-month risk of death of 17.5%, the combination of a 
creatinine-based and a cystatin C-based estimates of GFR augmented the discrimination. In 
these patients, the Chronic Kidney Disease Epidemiology Collaboration cystatin C equation 
(CKD-EPICysC) could redefine subgroups of patients with different outcomes, with those 
with a redefined estimated GFR <30 mL/min/1.73 m2 having a significantly worse prognosis, 
expressed by a 6-month risk of death of 31.4%. In this group of patients, the Net 
Reclassification Improvement (NRI) values indicated an expressive improvement in risk 
classification (46%) after addition of the CKD-EPICysC equation to the Cockcroft-Gault 
equation. In conclusion, in patients with moderate renal dysfunction, cystatin C-based 
estimation of GFR proved to add prognostic value to creatinine-based estimates of GFR 
alone, thus refining the prognostic exercise of clinicians. 
